ethyl (3S,4R)-4-amino-3-methoxypiperidine-1-carboxylate,hydrochloride

We are ethyl (3S,4R)-4-amino-3-methoxypiperidine-1-carboxylate,hydrochloride CAS:83863-71-2 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name: ethyl (3S,4R)-4-amino-3-methoxypiperidine-1-carboxylate,hydrochloride
CAS.NO:  83863-71-2
Synonyms:
Ethyl cis-4-amino-3-methoxypiperidine-1-carboxylate monohydrochloride

Molecular Formula:C9H19ClN2O3
Molecular Weight: 238.71200

Physical and Chemical Properties:
Density: /
Boiling point: /
Flash point:/
Refractive index: /

Specification:
Appearance:/
Purity:≥98%

 

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage:Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:Intermediates of Cisapride monophydrate  CAS:260779-88-2
Intermediates of Cisapride  CAS:81098-60-4

ethyl (3S,4R)-4-amino-3-methoxypiperidine-1-carboxylate,hydrochloride


Related News: Green Valley said it would launch the drug “very soon” in China. The company also aims to roll out a phase-3 clinical trial with sites in the United States, Europe and Asia in early 2020 to facilitate global regulatory approval of the drug.2-Bromo-5-fluorobenzaldehyde This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?1,3-Bis(isocyanatomethyl)benzene CAS:3634-83-1 This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?1,8-DIOODOOCTANO CAS:24772-63-2 Remogliflozin is economical than other similar agents currently available in sodium glucose co-transporter-2 (SGLT2) inhibitors class, which shall help for its better access among middle and low socio-economic strata of the society, he added.Beta Bionics is pursuing regulatory approval of its insulin-only bionic pancreas, followed by its dual-hormone system, which will also administer a glucagon analog in order to raise blood-sugar levels without the need to consume carbohydrates. Beta Bionics operates in Massachusetts and California.

Related Products
Product Name
ethyl 2-amino-4,5-bis(2-methoxyethoxy)benzoate,hydrochloride View Details
2-Bromopropionyl bromide View Details
2-Amino-3-nitro-4-picoline View Details
6-bromo-2-chloro-8-cyclopentyl-5-methylpyrido[2,3-d]pyrimidin-7-one manufacturer Dimethyl trisulfide manufacturer 2-[[3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]acetic acid manufacturer 3-BAP1NA-B manufacturer 8-amino-2-(2H-tetrazol-5-yl)chromen-4-one,hydrochloride manufacturer